89 related articles for article (PubMed ID: 23543442)
1. Chemokines fluctuate in the progression of primary breast cancer.
Wang J; He Q; Shao YG; Ji M
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):596-608. PubMed ID: 23543442
[TBL] [Abstract][Full Text] [Related]
2. Chemokine and chemokine receptors: a comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients.
Razmkhah M; Jaberipour M; Safaei A; Talei AR; Erfani N; Ghaderi A
Eur Cytokine Netw; 2012; 23(3):72-7. PubMed ID: 23078970
[TBL] [Abstract][Full Text] [Related]
3. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
5. CXC chemokines located in the 4q21 region are up-regulated in breast cancer.
Bièche I; Chavey C; Andrieu C; Busson M; Vacher S; Le Corre L; Guinebretière JM; Burlinchon S; Lidereau R; Lazennec G
Endocr Relat Cancer; 2007 Dec; 14(4):1039-52. PubMed ID: 18045955
[TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
8. HYOU1/Orp150 expression in breast cancer.
Stojadinovic A; Hooke JA; Shriver CD; Nissan A; Kovatich AJ; Kao TC; Ponniah S; Peoples GE; Moroni M
Med Sci Monit; 2007 Nov; 13(11):BR231-239. PubMed ID: 17968289
[TBL] [Abstract][Full Text] [Related]
9. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
10. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
12. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls.
Nariţa D; Seclaman E; Ursoniu S; Ilina R; Cireap N; Anghel A
Rom J Morphol Embryol; 2011; 52(4):1261-7. PubMed ID: 22203932
[TBL] [Abstract][Full Text] [Related]
13. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
14. The inflammatory chemokines CCL2 and CCL5 in breast cancer.
Soria G; Ben-Baruch A
Cancer Lett; 2008 Aug; 267(2):271-85. PubMed ID: 18439751
[TBL] [Abstract][Full Text] [Related]
15. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome.
Iguchi C; Nio Y; Itakura M
J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
18. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
19. Is there 'progression through grade' in ductal invasive breast cancer?
Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
[TBL] [Abstract][Full Text] [Related]
20. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
